Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?

Pharmacology & therapeutics - 1 Dec 2016

Magdy Tarek, Burmeister Brian T, Burridge Paul W

Abstract excerpt

The cardiotoxicity of certain chemotherapeutic agents is now well-established, and has led to the development of the field of cardio-oncology, increased cardiac screening of cancer patients, and limitation of patients' maximum cumulative chemotherapeutic dose. The effect of chemotherapeutic regimes on the heart largely involves cardiomyocyte death, leading to cardiomyopathy and heart failure, or the induction of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cardiotoxicity
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome-Wide Association Study

Share to Induced Pluripotent Stem Cells

Share to Myocytes, Cardiac

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 27609196
DOI: 10.1016/j.pharmthera.2016.09.009
PMCID: PMC5140687

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?PMID 27609196Read ↗

Personalized medicine in cardio-oncology: the role of induced pluripotent stem cellSemantic proximity Read ↗

Understanding the Mechanisms of Chemotherapy-Related Cardiotoxicity Employing hiPSC-Derived Cardiomyocyte Models for Drug Screening and the Identification of Genetic and Epigenetic VariantsSemantic proximity Read ↗

The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition.Semantic proximity Read ↗

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity.Semantic proximity Read ↗

Epigenetic Changes Associated With Anthracycline‐Induced CardiotoxicitySemantic proximity Read ↗

Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk.Semantic proximity Read ↗

Genetic Background in Patients with Cancer Therapy-Induced CardiomyopathySemantic proximity Read ↗

Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.Semantic proximity Read ↗

Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity.Semantic proximity Read ↗

Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer.Semantic proximity Read ↗

Prognostic Factors for Cardiotoxicity Among Children With Cancer: Definition, Causes and Diagnosis With Omics TechnologiesSemantic proximity Read ↗

Genetic factors in the pathogenesis of cardio-oncology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.